You are here

Pharma CEOs

Novartis CEO Says FDA Process Could Have Been Handled Better

Novartis CEO Says FDA Process Could Have Been Handled Better

Bloomberg

Flag link:

Allergan CEO Saunders lines up for $39M parachute after AbbVie buy

Allergan CEO Saunders lines up for $39M parachute after AbbVie buy

Fierce Pharma

Flag link:

Embattled Sun Pharma’s Dilip Shanghvi, with Rs 1 salary, ranks among lowest-paid pharma CEOs

Embattled Sun Pharma’s Dilip Shanghvi, with Rs 1 salary, ranks among lowest-paid pharma CEOs

Fierce Pharma

Flag link:

Teva CEO says manufacturing cuts will keep coming even after $3B reduction achieved

Teva CEO says manufacturing cuts will keep coming even after $3B reduction achieved

Fierce Pharma

Teva Pharmaceutical

drug manufacturing

Flag link:

Congress is going after drug prices. Pharma CEOs aren't panicking, yet

Congress is going after drug prices. Pharma CEOs aren't panicking, yet

Biopharma Dive

Flag link:

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

Endpoints

Flag link:

Mylan CEO Heather Bresch to retire after deal to merge with Pfizer's Upjohn closes

Mylan CEO Heather Bresch to retire after deal to merge with Pfizer's Upjohn closes

Marketwatch

Flag link:

Vertex's planned CEO handoff could signal stagnant growth to come: analyst

Vertex's planned CEO handoff could signal stagnant growth to come: analyst

Fierce Pharma

Vertex Pharmaceuticals

Reshma Kewalramani

Flag link:

Vertex Pharmaceuticals’ Jeffrey Leiden to step aside as CEO

Vertex Pharmaceuticals’ Jeffrey Leiden to step aside as CEO

Stat

Vertex Pharmaceuticals

Reshma Kewalramani

Flag link:

Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit

Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit

Stat

Gilead Sciences

Flag link:

Roche, Spark push back takeover deadline in $4.3 billion deal

Roche, Spark push back takeover deadline in $4.3 billion deal

Yahoo/Reuters

Spark Therapeutics

Flag link:

How Brent Saunders’ Allergan experiment failed

How Brent Saunders’ Allergan experiment failed

Stat

Flag link:

Forrester steps down as CEO of Verastem

Forrester steps down as CEO of Verastem

Fierce Biotech

Robert Forrester

Flag link:

Merck scouts replacements for CEO Frazier less than a year after scrapping retirement rule: report

Merck scouts replacements for CEO Frazier less than a year after scrapping retirement rule: report

Fierce Pharma

Flag link:

The top 20 highest-paid biopharma CEOs of 2018

The top 20 highest-paid biopharma CEOs of 2018

Fierce Pharma

Flag link:

Sanofi's Leadership Transition: What You Need To Know

Sanofi's Leadership Transition: What You Need To Know

Yahoo/Benzinga

Olivier Brandicourt

Flag link:

A struggling Sanofi is preparing to hire Novartis senior pharma exec Paul Hudson as new CEO, replacing Brandicourt -- report

A struggling Sanofi is preparing to hire Novartis senior pharma exec Paul Hudson as new CEO, replacing Brandicourt -- report

Endpoints

Olivier Brandicourt

Flag link:

From BIO meeting, Merck CEO Ken Frazier defends capitalism, drug industry

From BIO meeting, Merck CEO Ken Frazier defends capitalism, drug industry

Biopharma Dive

Flag link:

Follow the money: How biopharma CEOs and workers got paid in 2018

Follow the money: How biopharma CEOs and workers got paid in 2018

Biopharma Dive

Flag link:

Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline

Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline

Endpoints

Flag link:

Pages